Brawn Biotech Limited

BSE: BRAWN530207ISIN INE899B01015

Healthcare
Pharmaceuticals

Share price

₹23.16-0.11 (-0.47%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹26.64
52W low: ₹17.71
Off 52W high: -13.06%
1M return: -5.47%
3M return: +10.29%
6M return: +16.97%
1Y return: +15.17%
20D avg volume: 367
50 DMA: ₹23.16
200 DMA: ₹21.42

Key ratios Standalone

Market cap: ₹6.95 Cr
Current price: ₹23.16
52W high / low: ₹26.64 / ₹17.71
Face value: ₹10.00
P/E: 8.10
P/B: 1.64
EPS (TTM): ₹2.86
Book value / share: ₹14.12
ROE: 20.28%
ROCE: 0.00%
Operating margin: 3.03%
Net margin: 2.53%
Debt / equity: 0.00
Net debt: ₹-0.28 Cr
Interest cover: —
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -17.3 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	6.08	1.98	4.31	4.89	5.80	2.26	3.85	3.30	4.06	—
	0.14	0.18	0.09	0.09	0.09	0.09	0.00	0.00	—	—
	6.22	2.16	4.40	4.98	5.89	2.35	3.85	3.30	4.06	—
	6.06	2.51	4.35	4.91	5.65	2.85	4.28	3.64	4.59	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	2.23	1.30	3.54	5.36	3.91	3.18	8.00	2.45	2.75	—
	0.31	0.19	0.14	0.15	0.21	0.22	0.21	0.28	0.41	—
	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	—	—
	0.03	0.03	0.03	0.00	0.03	0.03	0.03	0.03	0.03	—
	0.54	0.57	0.50	0.57	0.46	0.64	0.58	0.56	0.40	—
	0.15	-0.36	0.05	0.07	0.24	-0.49	-0.43	-0.34	-0.53	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.15	-0.36	0.05	0.07	0.24	-0.49	-0.43	-0.34	-0.53	—
	0.00	-0.94	0.00	0.00	0.00	0.00	—	—	—	—
	0.15	0.58	0.05	0.07	0.24	-0.49	-0.43	-0.34	-0.53	—
	0.52	1.95	0.17	0.25	0.89	-1.65	-1.44	-0.96	-1.83	—
Key metrics
	0.18	-0.33	0.08	0.10	0.27	-0.46	-0.40	-0.31	-0.50	—
	3.00%	-16.70%	1.90%	2.00%	4.70%	-20.40%	-10.40%	-9.40%	-12.30%	—
	2.50%	29.30%	1.20%	1.40%	4.10%	-21.70%	-11.20%	-10.30%	-13.10%	—
	—	-6.30%	—	2.70%	—	-4.40%	—	—	—	—
	4.80%	-12.40%	11.90%	48.20%	42.90%	—	—	—	—	—
	-37.50%	218.40%	111.60%	120.60%	145.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	17.26	16.98	13.46	—
	0.50	0.45	0.09	—
	17.76	17.43	13.56	—
	17.83	17.43	15.36	—
	0.00	0.00	0.00	—
	12.43	14.11	16.38	—
	0.79	0.68	1.13	—
	0.03	0.00	0.00	—
	0.09	0.12	0.11	—
	2.18	2.10	2.18	—
	-0.09	0.00	-1.80	—
	0.00	0.00	0.00	—
	-0.09	0.00	-1.80	—
	-0.94	-0.94	0.00	—
	0.85	0.94	-1.80	—
	2.89	3.26	-5.87	—
Key metrics
	0.03	0.12	-1.69	—
	0.17%	0.70%	-12.60%	—
	4.92%	5.50%	-13.40%	—
	—	0.00%	-16.10%	—
	13.48%	26.20%	—	—
	—	152.20%	—	—
	—	0.08	-0.19	—
	—	0.12	-0.03	—
	—	0.00	0.00	—
	—	-0.28	-0.20	—
	—	-17.3	153.0	—
Balance sheet
	—	20.86	20.49	—
	—	17.12	17.50	—
	—	0.28	0.20	—
	—	3.55	3.41	—
	—	10.06	10.47	—
	—	1.94	2.20	—
	—	0.36	0.46	—
	—	14.41	8.24	—
	—	15.17	9.33	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	0.00	0.00	—
	—	4.34	3.36	—
Cash flow
	—	0.11	0.05	—
	—	-0.03	-0.24	—
	—	0.00	0.00	—
	—	0.03	0.24	—

Compounded growth

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +13.48%
Profit YoY (TTM): +183.33%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 52.94%

Holder	Type	Holding	Previous	Change
BRIJ RAJ GUPTA	Promoter	16.69%	—	—
Investor Education and Protection Fund (IEPF)	Public	14.40%	—	—
SHASHI BALA GUPTA	Promoter	8.27%	—	—
NITIN GUPTA	Promoter	6.45%	—	—
BRIJ BALA GUPTA	Promoter	6.30%	—	—
ADARSH KUMAR GUPTA	Promoter	6.25%	—	—
ATUL GUPTA	Promoter	2.36%	—	—
A B PHARMA P LTD	Promoter Group	2.27%	—	—
KAVITA GUPTA	Promoter	1.50%	—	—
DAKSHA KOTAK	Public	1.24%	—	—
Bhawna Goyal	Promoter	0.99%	—	—
MAMTA GUPTA	Promoter	0.44%	—	—
KUSH GUPTA	Promoter	0.43%	—	—
MAMTA GOEL	Promoter	0.36%	—	—
NUPUR VIBHUTI	Promoter Group	0.08%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Brawn Biotech Limited S	7	23.16	8.10	0.00%	+13.48% TTM	+183.33% TTM	+15.17%

Filings & corporate actions

Recent announcements

Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....29 Oct 2026 · Board Meeting / Board Meeting
Intimation under Reg 74(5)15 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure under Regulation 30 of SEBI LODR Regulations, 201529 Sep 2026 · Company Update / General
Scrutinizers Report attached along with voting results for 41st AGM29 Sep 2026 · AGM/EGM / AGM
Proceedings of 41st AGM29 Sep 2026 · AGM/EGM / AGM
Outcome of 41st Annual General Meeting29 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window for quarter ended 30.09.202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Letters sent to shareholders as per Reg 362 Sep 2026 · Company Update / General
Newspaper Publication for 41st Notice of AGM.2 Sep 2026 · Company Update / Newspaper Publication
ANNUAL REPORT FOR FY 2025-261 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of 41st AGM to be held on 29.09.20261 Sep 2026 · AGM/EGM / AGM
Publication of Un-audited financial results for the quarter ended June 30, 2026.14 Aug 2026 · Company Update / Newspaper Publication
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.13 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.13 Aug 2026 · Board Meeting / Outcome of Board Meeting
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results ....5 Aug 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5)8 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the quarter ended June 30, 2026.25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper publication of Audited Financial Results for Quarter and Year ended 31.03.202630 May 2026 · Company Update / Newspaper Publication
Intimation regarding non-applicability of Regulation 23(9)30 May 2026 · Company Update / General
BSE Intimation for Non-Applicability of Annual Secretarial Compliance Report under Regulation 24A30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
The Board of Directors today in their meeting considered and approved the audited financial results for quarter and year ended 31st March 202629 May 2026 · Result / Financial Results
Outcome of the Board Meeting of the Company held on 29th May 2026, and submissions of Audited Financial Results for the Quarter and year ended 31.03.202629 May 2026 · Board Meeting / Outcome of Board Meeting
Brawn Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited financial results ....21 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....13 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Certificate under Reg 74(5) of SEBI (DP) Regulations, 20187 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window from 01st April 2026 till 48 hours after the declaration of financial results for the quarter and financial year ended 31st March 2026.30 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Appointment of Internal Auditors and Secretarial Auditor for FY 2025-26.25 Mar 2026 · Board Meeting / Outcome of Board Meeting
Newspaper Advertisement for special window for transfer of physical shares.5 Mar 2026 · Company Update / Newspaper Publication
Newspaper publication of Unaudited Financial Results for Quarter and year to date ended 31.12.2025.16 Feb 2026 · Company Update / Newspaper Publication
OUTCOME OF BOARD MEETING HELD ON TODAY14 Feb 2026 · Board Meeting / Outcome of Board Meeting
Unaudited Financial Results for quarter and nine months ended 31.12.202514 Feb 2026 · Result / Financial Results
Prior Intimation for Board Meeting scheduled to be held on 14th February, 2026 to consider and approve unaudited financial results for the quarter ended 31st December, 2025.6 Feb 2026 · Others / Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1))
Appointment of Chief Financial Officer.30 Jan 2026 · Company Update / Change in Management
Certificate under Regulation 74(5) of SEBI (DP) Regulations 201813 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Resignation of Ms. Pooja Pandey (CFO and KMP).5 Jan 2026 · Company Update / Resignation of Chief Financial Officer (CFO)
General Announcement29 Dec 2025 · Company Update / General
INTIMATION REGARDING CLOSURE OF TRADING WINDOW27 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
ADDITIONAL DETAILS REQUIRED FOR CORPORATE ANNOUNCEMENT UNDER REGULATION 3022 Dec 2025 · Company Update / Resignation of Director
Disclosure under regulation 30 of the SEBI (LODR) Regulations for resigantion of Director25 Nov 2025 · Company Update / Cessation
Intimation of publication of unaudited financial result pursuant to regulation 47 of SEBI for second quarter and half year ended 30.09.202518 Nov 2025 · Company Update / Newspaper Publication

Board meetings

5 Nov 2026 Board Meeting - Financial Results
13 Aug 2026 Board Meeting - Financial Results